BioPharma Credit (BPCR.L) Stock Price

BioPharma Credit Price

LSE·CLOSED
0.98
​
Market closed

Revenue has compounded at 19.5% per year over the past 8 years to 140.23 M USD. Earnings per share have grown at 15.7% per year over the last 8 years. BioPharma Credit's net margin stands at 92.6%, down from 96.6% several years earlier. BioPharma Credit currently offers a dividend yield of about 7.11%. The payout ratio is around 61% of earnings. The dividend has grown at 17.0% per year over the past 8 years.

BioPharma Credit stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioPharma Credit business model & stock analysis

BioPharma Credit PLC was founded in 2017 and is an investment company specializing in financing in the biopharmaceutical and medical field. The company's goal is to identify investment opportunities in the rapidly growing biopharmaceutical market and generate lucrative returns for investors. BioPharma Credit's business model is based on providing loans to biotechnology and pharmaceutical companies. These loans are used to finance important projects and research that contribute to the development of new drugs and treatment methods. In return, the companies receive interest payments and loan repayments according to the agreements in the contract. BioPharma Credit pursues a differentiated strategy and invests in various sectors of the biopharmaceutical industry, such as cancer treatments, immunotherapies, or rare diseases. This includes riskier but potentially very profitable projects such as clinical trials or the market entry of new drugs. BioPharma Credit's portfolio currently includes approximately 26 investments in various areas of the biopharmaceutical industry. The company works closely with experienced partners such as the pharmaceutical company Pharmakia or the analysis firm IHS to conduct comprehensive due diligence and carefully assess opportunities and risks. Another important element of BioPharma Credit's business model is the investors. Most of BioPharma Credit's investors are institutional investors such as pension funds or insurance companies. Therefore, the company also takes into account the needs and requirements of these investors in the selection of borrowers and projects. BioPharma Credit offers its investors high transparency and protection against potential risks. All investments are made through a GmbH structure with fixed terms and fixed interest payments. In addition, the portfolio is regularly monitored and adjusted by an expert team to minimize risks and seize opportunities. Overall, BioPharma Credit offers its investors an attractive opportunity to benefit from the opportunities in the rapidly growing biopharmaceutical market without directly entering the risks and challenges of the biopharmaceutical industry. At the same time, BioPharma Credit contributes to driving important innovations and advancements in medicine and thereby generating societal and health benefits. One of BioPharma Credit's most successful investments in recent years, for example, was a loan to the British biotechnology company Orchard Therapeutics. This company specializes in the development of gene therapies for rare diseases. The loan from BioPharma Credit helped Orchard Therapeutics conduct a clinical trial and enter the market. Orchard Therapeutics' gene therapy has since been approved by the European Medicines Agency and has the potential to improve the lives of millions of people worldwide. Overall, the success story of BioPharma Credit demonstrates how investments in the field of biopharmaceuticals and medicine can contribute to driving important innovations and advancements in medicine while also achieving attractive returns for investors. The company has established itself as an experienced and reliable partner that, thanks to its expertise and networks, will continue to identify and realize successful investments in the biopharmaceutical sector in the future.

Frequently asked questions about BioPharma Credit

The business model of BioPharma Credit PLC revolves around investing in and providing loans to companies in the pharmaceutical and biotechnology sector. With a focus on credit opportunities, BioPharma Credit PLC aims to generate attractive risk-adjusted returns for its investors. By carefully evaluating the creditworthiness of potential borrowers, the company seeks to provide essential financing to support the growth and development of innovative drugs and therapies. Through its strategic investments, BioPharma Credit PLC aims to unlock value in the biopharmaceutical industry while mitigating risks associated with traditional equity investments.

BioPharma Credit PLC is primarily active in the pharmaceutical and biotechnology industries. With a focus on credit investments, the company provides financing solutions to a wide range of businesses operating in these sectors. Its expertise lies in supporting pharmaceutical companies in their research, development, and commercialization efforts. By strategically investing in the life sciences industry, BioPharma Credit PLC contributes to the advancement of innovative medicines and therapies. The company's prominent presence within the pharmaceutical and biotech sectors makes it a key player in supporting the growth and success of various companies within these industries.

The main competitors of BioPharma Credit PLC in the market include companies such as Ares Capital Corporation, Hercules Capital Inc., and Solar Capital Ltd. These companies also operate in the specialty finance sector and provide various funding solutions to the biopharmaceutical industry.

BioPharma Credit PLC, a leading healthcare investment trust, has a rich history and background. Established in 2017, the company focuses on providing long-term debt financing solutions to the global life sciences industry. With a strong investment management team and a diverse portfolio, BioPharma Credit PLC aims to generate consistent income and capital growth by investing in a range of healthcare-related assets. It has played a crucial role in supporting the biopharmaceutical industry's growth and innovation through its financial expertise. As a reputable player in the sector, BioPharma Credit PLC continues to create value for its shareholders while contributing to advancements in healthcare worldwide.

BioPharma Credit PLC, a renowned pharmaceutical financing company, has achieved several significant milestones. The company has successfully provided extensive capital to numerous biopharmaceutical companies, aiding in their research, development, and commercialization efforts. By facilitating financial investments, BioPharma Credit PLC has played a crucial role in supporting the growth and advancement of the pharmaceutical industry. Furthermore, the company's strategic partnerships and diverse portfolio of investments have contributed to its overall success. Through its commitment to funding innovative projects, BioPharma Credit PLC has positioned itself as a key player in the pharmaceutical financing sector, fostering further advancements in the life sciences industry.

BioPharma Credit PLC primarily operates in the United Kingdom, United States, Europe, and other international markets.

BioPharma Credit PLC represents a value-driven approach with a strong corporate philosophy focused on investing in the life sciences sector. As a company, BioPharma Credit PLC aims to provide long-term, stable income to investors by financing the growth and innovation of biopharmaceutical and healthcare companies. With a commitment to supporting advancements in medical research and development, BioPharma Credit PLC aligns its investment strategies with the goal of contributing to the betterment of global healthcare. By valuing innovation, scientific expertise, and ethical practices, BioPharma Credit PLC continuously seeks opportunities that align with its core values and corporate philosophy.

5 analysts currently rate the BioPharma Credit stock: 4 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the BioPharma Credit share trades at 0.90 EUR (0.98 USD).

The BioPharma Credit share (BPCR.L) is listed on 4 stock exchanges, including: London (BPCR.L), München (B3P.MU).

BioPharma Credit PLC is a leading specialist in the financing of biopharmaceutical companies. The company was founded in 2017 and is listed on the London Stock Exchange. BioPharma Credit PLC offers institutional investors the opportunity to invest in a portfolio of loans to biopharmaceutical companies worldwide. The business model of BioPharma Credit PLC is based on the understanding that biopharmaceutical companies are often faced with a financing gap. Due to the long development times and high costs of drug development, biopharmaceutical companies often require significant funding before they reach market readiness. Traditional financing options such as bank loans are usually not available due to the high risk and uncertain prospects for success. BioPharma Credit PLC offers alternative financing solutions by providing loans to biopharmaceutical companies. These loans are associated with a fixed interest rate and a fixed repayment plan. BioPharma Credit PLC applies strict criteria to minimize the risk of default and maximize long-term profitability. The portfolio of BioPharma Credit PLC includes loans to biopharmaceutical companies in all stages of the development process, from preclinical research to market launch. The loans can be used for research and development, clinical trials, working capital, and other purposes. BioPharma Credit PLC has built a diversified portfolio with different borrowers and geographic regions to spread the risk. BioPharma Credit PLC also has a performance-based management fee structure. The company charges an annual management fee of 1.5% of net assets and a success-based fee of 10% on all convincing returns. This model creates incentives for management to maximize the profitability of the portfolio. Overall, the business model of BioPharma Credit PLC offers unique advantages for investors. It provides an opportunity to invest in the rapidly growing biopharmaceutical sector without directly investing in individual companies. It minimizes risk through diversification and strict lending criteria. It also offers a fixed interest rate, which is attractive to investors seeking a consistent return. In summary, BioPharma Credit PLC has an innovative business model that meets the needs of biopharmaceutical companies and institutional investors. By providing alternative financing options for biopharmaceutical companies, BioPharma Credit PLC offers investors a unique opportunity to invest in this rapidly growing sector.

The revenue cannot currently be calculated for BioPharma Credit.

The profit cannot currently be calculated for BioPharma Credit.

The P/E ratio cannot be calculated for BioPharma Credit at the moment.

The P/S cannot be calculated for BioPharma Credit currently.

The Eulerpool Quality Score for BioPharma Credit is 2/10.

The ISIN of BioPharma Credit is GB00BDGKMY29. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of BioPharma Credit is A2DN3S. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of BioPharma Credit is BPCR.L. The ticker symbol is used to trade BioPharma Credit shares on the stock exchange.

Fair ValueTerminal
0.84 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Capital Markets
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website bpcruk.com
Currency
USD
Initial public offering
Mar 27, 2017
ISIN
GB00BDGKMY29
Cusip
G12808104
Sedol
BDGKMY2
Market capitalization
1.20 B USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
9.26
P/B Ratio
1.05
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
11.29 %
Dividend
Dividend yield
7.11 %
Payout Ratio
60.86 %
Dividend growth Ø5Y
—
Dividend payments per year
4
Dividend paid since
9 years
Dividend not reduced since
1 year
Dividend increased since
0 years
Dividend withholding tax
0.00 %
Last updated Nov 21, 2026, 9:38 PM

BioPharma Credit Peer Group

BioPharma Credit Ticker

LONDON · BPCP.LLONDON STOCK EXCHANGE · BPCR.LMUNICH · B3P.MUOTC · BOPCF

BioPharma Credit FIGI

BPCR:LN · BBG00G40LL63BPCRL:S1 · BBG00GBG8TD0BPCRGBP:EO · BBG00GBGFGD0BPCRGBP:XH · BBG00GBGFGH6BPCRGBP:XF · BBG00GBGFGK2BPCRGBP:XE · BBG00GBGFGM0BPCRGBP:XJ · BBG00GBGFGN9BPCRGBP:XL · BBG00GBGFGP7BPCRGBP:XG · BBG00GBGFGQ6BPCRGBP:XO · BBG00GBGFGR5BPCRGBP:XA · BBG00GBGFGX8BPCRGBP:E1 · BBG00GBGFGY7